Andreas Skolarikos

Summary

Affiliation: University of Athens
Country: Greece

Publications

  1. request reprint
    Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology. 2003;64:102-10 pubmed
    ..9 or non-responders. rHuEPO at a dose of 10,000 U thrice weekly prevents transfusions and development of significant anemia in patients with solid tumors receiving platinum-based chemotherapy. ..
  2. Bamias A, Karadimou A, Soupos N, Sotiropoulou M, Zagouri F, Haidopoulos D, et al. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience. Gynecol Oncol. 2011;123:37-42 pubmed publisher
    ..Risk stratification according to histology and grade is a useful discriminator of prognosis and can be used in the design of future studies. ..
  3. Bamias A, Tzannis K, Bamia C, Harshman L, Crabb S, Plimack E, et al. The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist. 2019;: pubmed publisher
    ..Therefore, deviations from eligibility criteria should be avoided. Consolidation surgery should be considered in responders. These data provide benchmarks for the study of novel therapies in aUTC. ..
  4. Bamias A, Karavasilis V, Gavalas N, Tzannis K, Samantas E, Aravantinos G, et al. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. Int J Clin Oncol. 2019;24:411-419 pubmed publisher
    ..Toxicity was considerable leading to high rate of treatment discontinuations. ClinicalTrials.gov: NCT01264341. ..
  5. Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). Crit Rev Oncol Hematol. 2015;93:36-49 pubmed publisher
  6. request reprint
    Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220-8 pubmed
    ..MVAC is more effective than DC in advanced urothelial cancer. G-CSF-supported MVAC is well tolerated and could be used instead of classic MVAC as first-line treatment in advanced urothelial carcinoma. ..
  7. request reprint
    Bamias A, Kyriakou F, Chorti M, Kavantzas N, Noni A, Kyroudi Voulgari A, et al. Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (H. Anticancer Res. 2008;28:2479-86 pubmed
    ..018). MVD may be a useful indicator of relapse in high-risk urothelial cancer treated with adjuvant chemotherapy. ..
  8. request reprint
    Bamias A, Lainakis G, Manios E, Koroboki E, Gyftaki R, Zakopoulos N, et al. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother. 2009;21:347-50 pubmed
    ..The application of such protocols instead of commonly used toxicity criteria should be further validated. ..
  9. Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2010;65:1009-21 pubmed publisher
    ..However, the possibility that a benefit by the addition of RT was not detected due to decreased power of the study should not be excluded. ..

More Information

Publications16

  1. Bamias A, Lainakis G, Kastritis E, Antoniou N, Alivizatos G, Koureas A, et al. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology. 2007;73:290-7 pubmed publisher
    ..Pretreatment quality of life and geriatric assessment may be useful in selecting patients likely to benefit from this treatment. ..
  2. Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116:1462-8 pubmed publisher
    ..6 months). Mucinous but not clear cell histology is associated with significantly worse prognosis in advanced ovarian cancer treated with combination platinum/paclitaxel. Different therapeutic strategies should be studied in this entity. ..
  3. Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, et al. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer. 2006;6:228 pubmed
    ..03). Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma. Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment. ..
  4. request reprint
    Bamias A, Bozas G, Antoniou N, Poulias I, Katsifotis H, Skolarikos A, et al. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol. 2008;53:323-31 pubmed
    ..Extraosseous metastases seem to be more sensitive than bone disease to this chemotherapy. ..
  5. Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, et al. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer. 2010;10:45 pubmed publisher
    ..Studies on risk stratification of patients with advanced RCC treated with targeted therapies are warranted. Our results suggest that a simpler than the MSKCC model can be developed. Such models should be further validated. ..
  6. Bamias A, Sotiropoulou M, Zagouri F, Trachana P, Sakellariou K, Kostouros E, et al. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. Eur J Cancer. 2012;48:1476-83 pubmed publisher
    ..The proposed model of ovarian tumourigenesis does not reflect tumour behaviour in advanced disease. Tumour-cell type is the most relevant histopathological prognostic factor in advanced ovarian cancer treated with platinum/paclitaxel. ..
  7. request reprint
    Bamias A, Deliveliotis C, Fountzilas G, Gika D, Anagnostopoulos A, Zorzou M, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:2150-4 pubmed
    ..We prospectively studied a cohort of patients who underwent surgery for high-risk carcinoma of the upper urinary tract to assess the feasibility of the combination of paclitaxel and carboplatin as adjuvant treatment...